Clinical trials: Sinusoidal Obstruction Syndrome
Veno-occlusive Disease
Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients
This study is to compare the efficacy and safety of defibrotide prophylaxis in addition to best supportive care versus best supportive care alone in the prevention of hepatic veno- occlusive disease (VOD) in adult and pediatric…
- Trial name
- NCT02851407
- Testing
- Defibrotide, Best Supportive Care
- Where
- 114 sites in United States, Australia and 12 more
- Volunteers
- 372 people
- Sponsor
- Jazz Pharmaceuticals
Sinusoidal Obstruction Syndrome, Complications of Bone Marrow Transplant
Using Ultrasound Elastography to Predict Development of SOS
Sinusoidal obstruction syndrome (SOS) is a potentially fatal hepatic veno-occlusive disease-affecting children following bone marrow transplantation (BMT).
- Trial name
- NCT02483481
- Testing
- shear wave ultrasound elastography
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Children's Mercy Hospital Kansas City
Bone Marrow Transplant Complications, Sinusoidal Obstruction Syndrome
Ultrasound Elastography to Predict Development of SOS
The long-term goal of our research is to accurately identify SOS patients who would benefit from defibrotide treatment using US SWE. The overall objective of this study is to validate SWE as an early diagnostic marker for SOS.
- Conditions
- Bone Marrow Transplant Complications, Sinusoidal Obstruction Syndrome, Veno-occlusive Disease, Stem Cell Transplant Complications
- Trial name
- NCT03858530
- Testing
- Ultrasound Examination
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Children's Mercy Hospital Kansas City
Severe Hepatic Veno-Occlusive Disease
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
The purpose of this study is to (1) demonstrate the efficacy and safety (toxicity) of 25 mg/kg/day of Defibrotide in patients with severe veno-occlusive disease (sVOD) and (2) evaluate serum and endothelial markers of…
- Trial name
- NCT00358501
- Testing
- Defibrotide
- Where
- 25 sites in United States, Canada
- Volunteers
- 134 people
- Sponsor
- Jazz Pharmaceuticals
Hepatic Veno-Occlusive Disease
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Single arm, open-label study to provide Defibrotide to patients diagnosed with VOD. Defibrotide is no longer available though the Emergency Use IND mechanism (also known as compassionate use, or single patient named use).
- Trial name
- Treatment IND (NCT00628498)
- Testing
- Defibrotide
- Where
- 125 sites in United States
- Volunteers
- 1,206 people
- Sponsor
- Jazz Pharmaceuticals